Efficacy of Once-Weekly Exenatide Versus Once or Twice Daily Insulin Detemir in Patients With Type 2 Diabetes

PHASE3CompletedINTERVENTIONAL
Enrollment

222

Participants

Timeline

Start Date

October 31, 2009

Primary Completion Date

July 31, 2011

Study Completion Date

December 31, 2011

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

exenatide once weekly

subcutaneous injection, 2mg, once a week

DRUG

insulin detemir

subcutaneous injection, with dosage titrated according to the determir label and published titration schedule, once or twice a day

Trial Locations (34)

Unknown

Research Site, Dublin

Research Site, Addlestone

Research Site, Bath

Research Site, Birmingham

Research Site, Blackburn

Research Site, Bournemouth

Research Site, Chippenham

Research Site, Derby

Research Site, Exeter

Research Site, High Wycombe

Research Site, Hull

Research Site, Leicester

Research Site, Liverpool

Research Site, London

Research Site, Manchester

Research Site, Merseyside

Research Site, Middlesbrough

Research Site, Newcastle

Research Site, Northampton

Research Site, Oldham

Research Site, Plymouth

Research Site, Portsmouth

Research Site, Sheffield

Research Site, Stevenage

Research Site, Suffolk

Research Site, Wakefield

Research Site, Wiltshire

Research Site, Aberdeen

Research Site, Dundee

Research Site, Carmathen

Research Site, Swansea

Research Site, Wrexham

Research Site, Leytonstone

Research Site, Livingston

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Eli Lilly and Company

INDUSTRY

lead

AstraZeneca

INDUSTRY